Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

"While the rescinded grant is undoubtedly a setback, it also sharpens our focus on the solid foundation already established ...

A Massachusetts-based wound care and sports medicine company announced plans for its brand-new biomanufacturing facility ...

A recovery from this prolonged and painful market downturn will require a major attitude adjustment from biotech management ...

The Bay Area's biotech industry faces an uncertain future after 50 years. But industry leaders see a history of resilience ...

Dr. Aaron Carrithers brings a founder’s mindset and extensive firsthand experience, guiding biotech teams through complicated ...

Plus: Rockville man arrested for filming woman in fitting room at Montgomery mall; Montgomery College launches cybersecurity ...

New Orleans biotech South Rampart Pharma advances non-opioid pain drug with $8M funding from Ochsner Ventures and Gulf South ...

AmplifyBio said in a statement April 4, saying the decision to close followed months of efforts to keep the four-year-old firm afloat.

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Chicago’s life sciences market is the smallest of any major U.S. market by square footage yet has a vacancy rate of 43.3 ...